Contents:
Real-https://1investing.in/ analyst ratings, insider transactions, earnings data, and more. Karuna Therapeutics’s market cap is calculated by multiplying KRTX’s current stock price of $198.44 by KRTX’s total outstanding shares of 34,473,905. The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
- Get MarketBeat All Access Free for 30 DaysJoin thousands of other investors who make better investing decisions with our premium tools.
- While Karuna Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
- Each bar represents the previous year of ratings for that month.
- Bank of New York Mellon Corp now owns 211,678 shares of the company’s stock valued at $26,839,000 after buying an additional 120,709 shares during the last quarter.
- Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
This is a decrease of -47% compared to the previous 30 days. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Karuna Therapeutics has been rated by Cantor Fitzgerald, HC Wainwright, JMP Securities, Wedbush, and Wells Fargo & Company in the past 90 days.
Add to Portfolio
If you had invested in Karuna Therapeutics stock at $20.02, your return over the last 3 years would have been 891.21%, for an annualized return of 114.81% . Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Investing.com – U.S. equities were higher at the close on Monday, as gains in the Consumer Services, Consumer Goods and Technology sectors propelled shares higher. Provide specific products and services to you, such as portfolio management or data aggregation. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.
MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… KRTX longKRTX speculation If KRTX can hold the $98.00-$100.00 level and momentum continues this week there is room to $120 Pullback to $98 would make for an ideal entry. If the long setup fails, There is a good short opportunity under $95.80. KRTX speculation If KRTX can hold the $98.00-$100.00 level and momentum continues this week there is room to $120 Pullback to $98 would make for an ideal entry. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.
WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Karuna Therapeutics stock was originally listed at a price of $20.02 in Jun 28, 2019.
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies. According to analysts, Karuna Therapeutics’s stock has a predicted upside of 26.22% based on their 12-month price targets. Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. The company also focuses on developing other muscarinic-targeted drug candidates.
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.11%
Real-the hongkong and shanghai hotels last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Shares of Karuna Therapeutics Inc. soared 42.6% in premarket trading on Monday after the company said its experimental treatment for schizophrenia met the primary endpoint in a Phase 3 clinical trial. In the past three months, Karuna Therapeutics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,981,570.00 in company stock.
- The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
- According to analysts’ consensus price target of $276.87, Karuna Therapeutics has a forecasted upside of 35.0% from its current price of $205.11.
- CompareKRTX’s historical performanceagainst its industry peers and the overall market.
- Shares of Karuna Therapeutics Inc. soared 42.6% in premarket trading on Monday after the company said its experimental treatment for schizophrenia met the primary endpoint in a Phase 3 clinical trial.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Get MarketBeat All Access Free for 30 DaysJoin thousands of other investors who make better investing decisions with our premium tools. Access advanced stock screeners, portfolio monitoring tools, proprietary research reports, and more.
Cerevel Test Data Scrambles Schizophrenia Stocks
Cambridge Investment Research Advisors Inc. now owns 2,172 shares of the company’s stock valued at $275,000 after buying an additional 105 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Karuna Therapeutics by 53.7% during the 1st quarter. MetLife Investment Management LLC now owns 12,299 shares of the company’s stock worth $1,559,000 after buying an additional 4,297 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Karuna Therapeutics by 3.0% in the 1st quarter. Rhumbline Advisers now owns 23,080 shares of the company’s stock worth $2,926,000 after acquiring an additional 669 shares in the last quarter. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
Karuna Therapeutics has a short interest ratio (“days to cover”) of 5.2. Sign-up to receive the latest news and ratings for KRTX and its competitors with MarketBeat’s FREE daily newsletter. Overall, this stock passed 10/33 due dilligence checks and has average fundamentals, according to our automated analysis. Karuna Therapeutics Inc. reported Q3 EPS of ($2.38), $0.27 worse than the analyst estimate of ($2.11). Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.
The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Market cap is the total market value of a publicly traded company’s outstanding shares. Karuna Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. While Karuna Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys. Intraday Data provided by FACTSET and subject to terms of use.
The company’s average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Karuna Therapeutics, Inc operates as a clinical-stage biopharmaceutical company. Engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Karuna Therapeutics is -23.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Karuna Therapeutics Reports Positive Results from Phase 3 Trial of KarXT
15 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” KRTX shares.
KRTX gap fill lower targets b/t $19-$32A strong bearish RSI divergence showing here with a gap down in the level, buy orders would be set nicely there or short into that level. A strong bearish RSI divergence showing here with a gap down in the level, buy orders would be set nicely there or short into that level. We’d like to share more about how we work and what drives our day-to-day business. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
Piper Sandler began coverage on Karuna Therapeutics in a report on Thursday, January 5th. They issued an “overweight” rating and a $285.00 price target for the company. Wedbush reaffirmed an “outperform” rating on shares of Karuna Therapeutics in a research note on Tuesday, March 21st. HC Wainwright dropped their price objective on Karuna Therapeutics from $320.00 to $300.00 and set a “buy” rating for the company in a report on Tuesday, March 28th.
In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. The chart below shows how a company’s share price and consensus price target have changed over time. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Analysts like Karuna Therapeutics more than other Medical companies. The consensus rating for Karuna Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
To see all exchange delays and terms of use please see Barchart’s disclaimer. 6.08% of the outstanding shares of Karuna Therapeutics have been sold short. Information is provided ‘as-is’ and solely for informational purposes and is not advice.
Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in shares of Karuna Therapeutics by 19.6% in the 1st quarter. JPMorgan Chase & Co. now owns 20,218 shares of the company’s stock worth $2,563,000 after purchasing an additional 3,317 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Karuna Therapeutics by 132.7% in the first quarter. Bank of New York Mellon Corp now owns 211,678 shares of the company’s stock valued at $26,839,000 after buying an additional 120,709 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Karuna Therapeutics by 5.1% during the first quarter.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Please log in to your account or sign up in order to add this asset to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareKRTX’s historical performanceagainst its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion. By creating a free account, you agree to our terms of service.
